Evidence map›Paper›PMID 34677830›Full record

ArticleTransfusion2022

Active surveillance of serious adverse events following transfusion of COVID-19 convalescent plasma.

Erica Swenson, Lisa Kanata Wong, Perrin Jhaveri, Yingjie Weng, Shanthi Kappagoda, Suchitra Pandey, Angelica Pritchard, Angela Rogers, Stephen Ruoss, Aruna Subramanian and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. COVID-19 convalescent plasma: current status, lessons from the past and future perspectives.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2022
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Erica SwensonDepartment of Pathology, Stanford University, Stanford, California, USA.ORCID 0000-0002-7195-9644
Lisa Kanata WongDepartment of Pathology, Stanford University, Stanford, California, USA.ORCID 0000-0001-9051-2090
Perrin JhaveriDepartment of Hematology, Kaiser Permanente, Renton, Washington, USA.
Yingjie WengDepartment of Medicine, Quantitative Sciences Unit, Stanford University, Stanford, California, USA.
Shanthi KappagodaDepartment of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California, USA.
Suchitra PandeyDepartment of Pathology, Stanford University, Stanford, California, USA.ORCID 0000-0003-3614-2353
Angelica PritchardDepartment of Emergency Medicine, Stanford University, Stanford, California, USA.ORCID 0000-0002-6147-2955
Angela RogersDepartment of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University, Stanford, California, USA.
Stephen RuossDepartment of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University, Stanford, California, USA.
Aruna SubramanianDepartment of Medicine, Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California, USA.
Hua ShanDepartment of Pathology, Stanford University, Stanford, California, USA.
Marie HollenhorstDepartment of Pathology, Stanford University, Stanford, California, USA.ORCID 0000-0002-2237-6645

Funding

Stanford Center for Clinical & Translational Education and Research (Spectrum)UL1TR003142 · NCATS · STANFORD UNIVERSITY · PI O'HARA, RUTH M · 2019 to 2023
$45.0M
NCATS NIH HHS UL1 TR003142NCATS NIH HHS UL1TR003142
6 · The paper itself

Abstract

backgroundThe reported incidence of adverse reactions following Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) transfusion has generally been lower than expected based on the incidence of transfusion reactions that have been observed in studies of conventional plasma transfusion. This raises the concern for under-reporting of adverse events in studies of CCP that rely on passive surveillance strategies. MATERIALS AND

methodsOur institution implemented a protocol to actively identify possible adverse reactions to CCP transfusion. In addition, we retrospectively reviewed the charts of inpatients who received CCP at Stanford Hospital between May 13, 2020 and January 31, 2021. We determined the incidence of adverse events following CCP transfusion.

resultsA total of 49 patients received CCP. Seven patients (14%) had an increased supplemental oxygen requirement within 4 h of transfusion completion, including one patient who was intubated during the transfusion. An additional 11 patients (total of 18, 37%) had increased oxygen requirements within 24 h of transfusion, including 3 patients who were intubated. Six patients (12%) fulfilled criteria for transfusion-associated circulatory overload (TACO).

conclusionUsing an active surveillance strategy, we commonly observed adverse events following the transfusion of CCP to hospitalized patients. It was not possible to definitively determine whether or not these adverse events are related to CCP transfusion. TACO was likely over-diagnosed given overlap with the manifestations of COVID-19. Nevertheless, these results suggest that the potential adverse effects of CCP transfusion may be underestimated by reports from passive surveillance studies.

Indexed as

Blood Component TransfusionCOVID-19COVID-19 SerotherapyHumansImmunization, PassiveOxygenPlasmaRetrospective StudiesTreatment OutcomeOxygen

Identifiers

PMID34677830
PMCPMC8661846

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.